Literature DB >> 32759008

Fenofibrate increases the amount of sulfatide which seems beneficial against Covid-19.

Karsten Buschard1.   

Abstract

Fenofibrate, which is a PPAR-alfpha agonist, increases the level of sulfatide. In this letter we hypothesize on the background of various findings that this is beneficial against COVID-19. Fenofibrate has been used for decades against hypercholesterolemia and has no serious side effects. Therefore, a trial giving fenofibrate to patients with corona virus infection is recommended.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Corona virus; Fenofibrate; Serine; Sphingolipids; Sulfatide

Mesh：

Substances：

Year:  2020        PMID： 32759008      PMCID： PMC7372998          DOI： 10.1016/j.mehy.2020.110127

Source DB:  PubMed          Journal:  Med Hypotheses        ISSN： 0306-9877            Impact factor:   1.538


  7 in total

1.  Effects of hypertension and antihypertensive treatments on sulfatide levels in serum and its metabolism.

Authors:  Ran Guo; Xiao Hu; Yosuke Yamada; Makoto Harada; Takero Nakajima; Toshihide Kashihara; Mitsuhiko Yamada; Toshifumi Aoyama; Yuji Kamijo
Journal:  Hypertens Res       Date:  2018-12-10       Impact factor: 3.872

2.  Sulfatide negatively regulates the fusion process of human parainfluenza virus type 3.

Authors:  Tadanobu Takahashi; Kazuhiko Ito; Keijo Fukushima; Masahiro Takaguchi; Takuya Hayakawa; Yasuo Suzuki; Takashi Suzuki
Journal:  J Biochem       Date:  2012-07-20       Impact factor: 3.387

3.  Developmental expression of the type I diabetes related antigen sulfatide and sulfated lactosylceramide in mammalian pancreas.

Authors:  Maria Blomqvist; Anne Kaas; Jan-Eric Månsson; Bent Formby; Britt-Marie Rynmark; Karsten Buschard; Pam Fredman
Journal:  J Cell Biochem       Date:  2003-05-15       Impact factor: 4.429

4.  Low serum concentration of sulfatide and presence of sulfated lactosylceramid are associated with Type 2 diabetes. The Skaraborg Project.

Authors:  K Buschard; P Fredman; E Bøg-Hansen; M Blomqvist; J Hedner; L Råstam; U Lindblad
Journal:  Diabet Med       Date:  2005-09       Impact factor: 4.359

5.  Sulfatide controls insulin secretion by modulation of ATP-sensitive K(+)-channel activity and Ca(2+)-dependent exocytosis in rat pancreatic beta-cells.

Authors:  Karsten Buschard; Marianne Høy; Krister Bokvist; Hervør L Olsen; Sten Madsbad; Pam Fredman; Jesper Gromada
Journal:  Diabetes       Date:  2002-08       Impact factor: 9.461

6.  Sulfatide is associated with insulin granules and located to microdomains of a cultured beta cell line.

Authors:  Maria Blomqvist; Thomas Osterbye; Jan-Eric Månsson; Thomas Horn; Karsten Buschard; Pam Fredman
Journal:  Glycoconj J       Date:  2002-07       Impact factor: 2.916

7.  Fenofibrate increases very-long-chain sphingolipids and improves blood glucose homeostasis in NOD mice.

Authors:  Laurits J Holm; Martin Haupt-Jorgensen; Jano D Giacobini; Jane P Hasselby; Mesut Bilgin; Karsten Buschard
Journal:  Diabetologia       Date:  2019-08-13       Impact factor: 10.122
  7 in total
  9 in total

1.  The Hyperlipidaemic Drug Fenofibrate Significantly Reduces Infection by SARS-CoV-2 in Cell Culture Models.

Authors:  Scott P Davies; Courtney J Mycroft-West; Isabel Pagani; Harriet J Hill; Yen-Hsi Chen; Richard Karlsson; Ieva Bagdonaite; Scott E Guimond; Zania Stamataki; Marcelo Andrade De Lima; Jeremy E Turnbull; Zhang Yang; Elisa Vicenzi; Mark A Skidmore; Farhat L Khanim; Alan Richardson
Journal:  Front Pharmacol       Date:  2021-08-06       Impact factor: 5.988

Review 2.  Lipid homeostasis and mevalonate pathway in COVID-19: Basic concepts and potential therapeutic targets.

Authors:  Maria Chiara Proto; Donatella Fiore; Chiara Piscopo; Cristina Pagano; Mario Galgani; Sara Bruzzaniti; Chiara Laezza; Patrizia Gazzerro; Maurizio Bifulco
Journal:  Prog Lipid Res       Date:  2021-04-26       Impact factor: 16.195

Review 3.  Investigating Lipid-Modulating Agents for Prevention or Treatment of COVID-19: JACC State-of-the-Art Review.

Authors:  Azita H Talasaz; Parham Sadeghipour; Maryam Aghakouchakzadeh; Isaac Dreyfus; Hessam Kakavand; Hamid Ariannejad; Aakriti Gupta; Mahesh V Madhavan; Benjamin W Van Tassell; David Jimenez; Manuel Monreal; Muthiah Vaduganathan; John Fanikos; Dave L Dixon; Gregory Piazza; Sahil A Parikh; Deepak L Bhatt; Gregory Y H Lip; Gregg W Stone; Harlan M Krumholz; Peter Libby; Samuel Z Goldhaber; Behnood Bikdeli
Journal:  J Am Coll Cardiol       Date:  2021-10-19       Impact factor: 27.203

4.  The role of fenofibrate in the treatment of COVID-19.

Authors:  Farah Yasmin; Muhammad Hamayl Zeeshan; Irfan Ullah
Journal:  Ann Med Surg (Lond)       Date:  2021-11-03

5.  Aberrant Cholesterol Metabolic Genes Regulation in a Negative Feedback Loop Induced by an Alphacoronavirus.

Authors:  Hao-Yu Liu; Haotian Gu; Huan Qu; Wenbin Bao; Yanhua Li; Demin Cai
Journal:  Front Nutr       Date:  2022-03-18

Review 6.  Chemokine-Based Therapeutics for the Treatment of Inflammatory and Fibrotic Convergent Pathways in COVID-19.

Authors:  Dana R Julian; Megan A Kazakoff; Akhil Patel; Jesse Jaynes; Monte S Willis; Cecelia C Yates
Journal:  Curr Pathobiol Rep       Date:  2021-12-08

Review 7.  Fenofibrate for COVID-19 and related complications as an approach to improve treatment outcomes: the missed key for Holy Grail.

Authors:  Shadi Salem Alkhayyat; Hayder M Al-Kuraishy; Ali I Al-Gareeb; Maisra M El-Bouseary; Amal M AboKamer; Gaber El-Saber Batiha; Jesus Simal-Gandara
Journal:  Inflamm Res       Date:  2022-08-08       Impact factor: 6.986

Review 8.  Research and development of Chinese anti-COVID-19 drugs.

Authors:  Xiwei Ji; Xiangrui Meng; Xiao Zhu; Qingfeng He; Yimin Cui
Journal:  Acta Pharm Sin B       Date:  2022-09-13       Impact factor: 14.903

9.  Blood gene expression predicts intensive care unit admission in hospitalised patients with COVID-19.

Authors:  Rebekah Penrice-Randal; Xiaofeng Dong; Andrew George Shapanis; Aaron Gardner; Nicholas Harding; Jelmer Legebeke; Jenny Lord; Andres F Vallejo; Stephen Poole; Nathan J Brendish; Catherine Hartley; Anthony P Williams; Gabrielle Wheway; Marta E Polak; Fabio Strazzeri; James P R Schofield; Paul J Skipp; Julian A Hiscox; Tristan W Clark; Diana Baralle
Journal:  Front Immunol       Date:  2022-09-20       Impact factor: 8.786
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.